Other, Other, Publications Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance
Immunosynthen, Publications, XMT-2056 XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses
Dolaflexin, Publications, UpRi (XMT-1536) NaPi2b Expression in High-Grade Serous Ovarian Cancer: Results From Combined Data Sets
Dolaflexin, Publications, UpRi (XMT-1536) Archival vs Fresh Tumor Samples for Assessing the Gene Expression of NaPi2b and Immune-Related Genes in the Phase 1 Study of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
Dolaflexin, Publications, UpRi (XMT-1536) UP-NEXT (GOG-3049/ENGOT-ov71-NSGO-CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC) in Platinum-Sensitive Recurrent Ovarian Cancer
Dolaflexin, Publications, UpRi (XMT-1536) UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Antibody-Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer
Dolaflexin, Publications, UpRi (XMT-1536) UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of the XMT-1536-1 Trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC), in Platinum-Resistant Ovarian Cancer
Dolaflexin, Publications, UpRi (XMT-1536) Comparison of NaPi2b Expression From Paired Tissue Samples in a Clinical Study of Upifitamab Rilsodotin (UpRi; XMT-1536) Supports a Strategy of Testing in Archival Material
